Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
112 studies found for:    daclatasvir
Show Display Options
Rank Status Study
1 Not yet recruiting Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment
Condition: Chronic Hepatitis C
Intervention: Drug: Daclatasvir and Asunaprevir
2 Completed
Has Results
Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment
Condition: Hepatitis C
Intervention: Drug: Daclatasvir
3 Completed
Has Results
Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV
Condition: Hepatitis C
Interventions: Drug: Daclatasvir;   Drug: Sofosbuvir
4 Recruiting Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV
Condition: Hepatitis C
Interventions: Drug: daclatasvir;   Drug: asunaprevir;   Drug: Ribavirin
5 Completed
Has Results
Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Participants
Condition: Hepatitis C
Interventions: Drug: Daclatasvir;   Drug: Darunavir;   Drug: Ritonavir;   Drug: Lopinavir/Ritonavir
6 Recruiting Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT)
Condition: Hepatitis C, Chronic
Interventions: Drug: Daclatasvir + Sofosbuvir;   Drug: Simeprevir + Sofosbuvir
7 Completed Bioequivalence Study of Daclatasvir From Daclatasvir Zeta 60 mg Film Coated Tablets (Zeta Pharm Pharmacuetical Industries, Egypt) and Clatazev 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)
Condition: Healthy
Interventions: Drug: Daclatasvir Zeta;   Drug: Clatazev
8 Completed
Has Results
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
Condition: Hepatitis C
Interventions: Drug: Daclatasvir;   Drug: Sofosbuvir
9 Withdrawn A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 3
Condition: Hepatitis C
Interventions: Drug: Daclatasvir;   Drug: Sofosbuvir;   Drug: Ribavirin
10 Completed A Drug-drug Interaction Study Between Daclatasvir and Metformin
Conditions: Hepatitis C;   Diabetes Mellitus;   Insulin Resistance
Interventions: Drug: Daclatasvir;   Drug: Metformin
11 Completed Bioequivalence Study of Daclatasvir From Daktavira 60 mg Film Coated Tablets ( European Egyptian Pharmaceutical Industries, Egypt) Versus Daklinza 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)
Condition: Healthy
Interventions: Drug: Daktavira;   Drug: Daklinza
12 Active, not recruiting Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial
Condition: Hepatitis C
Intervention: Drug: Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)
13 Completed A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants
Condition: Hepatitis C, Chronic
Interventions: Drug: Simeprevir;   Drug: Daclatasvir
14 Active, not recruiting An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease
Condition: Hepatitis C, Chronic
Interventions: Drug: Simeprevir;   Drug: Daclatasvir;   Drug: Sofosbuvir
15 Withdrawn Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir, and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen
Condition: Hepatitis C Virus Genotype 4 Infection
Intervention: Drug: .Asunaprevir, Daclatasvir and BMS - 791325
16 Active, not recruiting A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
Conditions: Chronic Hepatitis C;   Hepatitis C Virus;   Genotype 3 Hepatitis C Virus
Interventions: Drug: ABT-493/ABT-530;   Drug: sofosbuvir;   Drug: daclatasvir
17 Withdrawn A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1)
Condition: Hepatitis C
Interventions: Drug: Daclatasvir;   Drug: Sofosbuvir
18 Recruiting The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure
Condition: Hepatitis C
Intervention: Drug: Daclatasvir plus Asunaprevir
19 Active, not recruiting A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection
Condition: Hepatitis C
Interventions: Drug: Daclatasvir;   Drug: Asunaprevir
20 Completed A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C
Conditions: Chronic Hepatitis C;   CHC;   HCV;   Hepatitis C
Interventions: Drug: VX-135;   Drug: Daclatasvir

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.